Investor profile
Cambridge Innovation Capital
See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
Cambridge Innovation Capital (CIC) was founded in 2013 out of a unique relationship with the University of Cambridge and serves as a preferred investor for the university, giving it privileged access to the most inspiring ideas and people in life sciences and deep tech. CIC backs world-leading, knowledge-intensive businesses with an affiliation to Cambridge — Europe's leading hub for innovation — investing in disruptive deep-tech sectors including artificial intelligence, quantum technologies, autonomous systems, therapeutics, medtech/diagnostics, digital health, and genomics/proteomics. Managing over £600 million in assets across multiple funds, CIC provides not only capital but also deep scientific expertise and strategic guidance to help founders build category-leading global companies. As Andrew Williamson, Managing Partner, has stated: "Cambridge is at the forefront of innovation in deep tech and life sciences. We want to enable the world's leading entrepreneurs to build hugely disruptive global companies" — supporting them from early-stage seed through to growth-stage scale-up, with a long-term investment model oriented toward financial success and global impact.
Notable quotes
“Cambridge is at the forefront of innovation in deep tech and life sciences. Our new EIR programme will provide academics and researchers with access to the £100m we are committing to University of Cambridge spinouts as they continue to develop breakthrough technologies. This expansion of CIC's long-standing partnership with the University of Cambridge, which provides unique access to the university's academics and research, will help support the UK's economic growth by developing the next generation of world-class companies.”
“CIC has traditionally invested in early-stage opportunities around Cambridge and has seen many of these companies mature into highly commercial businesses developing proven technologies. With this new fund we will support our portfolio companies, and scaleups from the UK ecosystem, as they reach a defining moment in their growth – and at exactly the point where the UK often loses its most exciting businesses. We want to be a part of that change.”
“We are delighted to be able to support long-time Cambridge Innovation Capital adviser, William Tunstall-Pedoe, as he looks to tackle some of the hardest challenges in AI. CIC was established to enable the world's leading entrepreneurs to build hugely disruptive global companies, so we are pleased to be co-investing alongside Amadeus Capital Partners and Octopus Ventures to support William and the Unlikely AI team.”
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| Trent AI | Seed | $13m | 2026-04-07 |
| Immutrin | Series A | — | 2026-03-24 |
| BeyondMath | Seed | $19m | 2026-02-25 |
| T-Therapeutics | Series A | — | 2025-11-13 |
| Riverlane | Series C | $75m | 2024-08-01 |
| CMR Surgical | Series D | $600m | 2021-06-01 |
| Bicycle Therapeutics | Series B | — | 2019-01-01 |
| Pragmatic Semiconductor | Series C | $50m | 2022-01-01 |
| Gyroscope Therapeutics | Series B | — | 2019-09-01 |
| Microbiotica | Series A | — | 2020-01-01 |
Frequent co-investors
| VC firm | Deals together |
|---|---|
| Parkwalk Advisors | 8 |
| Amadeus Capital Partners | 7 |
| IP Group | 6 |
| Octopus Ventures | 5 |
| Syncona | 4 |
| Tencent | 3 |
Fit check
Is Cambridge Innovation Capital a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit